It is estimated that one in four Canadians has symptoms of constipation and an estimated 38% of Canadians report constipation within the previous 12 months.According to IQVIA the total Canadian laxative and antispasmodic market (prescription and OTC) was valued at over CDN $200 million for the 12 months ending December 2018.
Cipher acquired the Canadian rights to develop, market, distribute and sell TRULANCE® from Bausch Health Companies Inc.
Cipher anticipates several key milestones in 2019 that will continue to enhance long term value, including:
Regulatory approval for A-101 from Health Canada in Q4 2019
Top line results for MOB-015 Phase 3 study in North America expected in late Q4 2019
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.